KR20150002713A - 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체 - Google Patents

단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체 Download PDF

Info

Publication number
KR20150002713A
KR20150002713A KR1020147030291A KR20147030291A KR20150002713A KR 20150002713 A KR20150002713 A KR 20150002713A KR 1020147030291 A KR1020147030291 A KR 1020147030291A KR 20147030291 A KR20147030291 A KR 20147030291A KR 20150002713 A KR20150002713 A KR 20150002713A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
alkoxy
substituted
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147030291A
Other languages
English (en)
Korean (ko)
Inventor
볼프강 라시들로
Original Assignee
뉴로포레 테라피스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로포레 테라피스, 인코포레이티드 filed Critical 뉴로포레 테라피스, 인코포레이티드
Publication of KR20150002713A publication Critical patent/KR20150002713A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147030291A 2012-03-28 2013-03-15 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체 Withdrawn KR20150002713A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616771P 2012-03-28 2012-03-28
US61/616,771 2012-03-28
PCT/US2013/032552 WO2013148365A1 (en) 2012-03-28 2013-03-15 Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
KR20150002713A true KR20150002713A (ko) 2015-01-07

Family

ID=49261100

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030291A Withdrawn KR20150002713A (ko) 2012-03-28 2013-03-15 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체

Country Status (15)

Country Link
US (1) US9527852B2 (enExample)
EP (1) EP2830608B8 (enExample)
JP (1) JP6159388B2 (enExample)
KR (1) KR20150002713A (enExample)
CN (1) CN104363903A (enExample)
AU (1) AU2013240219A1 (enExample)
CA (1) CA2867175A1 (enExample)
ES (1) ES2768602T3 (enExample)
HK (1) HK1202452A1 (enExample)
IL (1) IL234825A0 (enExample)
IN (1) IN2014DN08633A (enExample)
MX (1) MX2014011615A (enExample)
NZ (1) NZ631388A (enExample)
RU (1) RU2014143242A (enExample)
WO (1) WO2013148365A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ722487A (en) 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
WO2016040780A1 (en) * 2014-09-11 2016-03-17 Neuropore Therapies, Inc. Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
JP7073385B2 (ja) 2017-01-26 2022-05-23 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体
RU2019126170A (ru) 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
EP3573981B1 (en) 2017-01-26 2022-03-16 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712297D1 (de) 1996-01-26 2005-06-09 Altana Pharma Ag 3-alkylimidazopyridine
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
CA2389360C (en) 1999-11-16 2008-06-03 Steffen Breitfelder Urea derivatives as anti-inflammatory agents
IL155645A0 (en) * 2000-10-30 2003-11-23 Kudos Pharm Ltd Phthalazinone derivatives
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
JP2006520333A (ja) 2003-03-14 2006-09-07 ハー・ルンドベック・アクチエゼルスカベット 置換されたアニリン誘導体
AU2004222626B2 (en) 2003-03-21 2010-06-24 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
US7750160B2 (en) * 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
MX2008013599A (es) 2006-04-21 2008-10-31 Smithkline Beechman Corp Antagonistas del receptor il-8.
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JP5922031B2 (ja) 2009-12-16 2016-05-24 ニューロポア セラピーズ，インコーポレイティド 化合物

Also Published As

Publication number Publication date
ES2768602T3 (es) 2020-06-23
RU2014143242A (ru) 2016-05-20
JP2015515465A (ja) 2015-05-28
WO2013148365A1 (en) 2013-10-03
NZ631388A (en) 2016-01-29
IN2014DN08633A (enExample) 2015-05-22
US20150166543A1 (en) 2015-06-18
CN104363903A (zh) 2015-02-18
EP2830608B1 (en) 2019-12-11
EP2830608A1 (en) 2015-02-04
JP6159388B2 (ja) 2017-07-05
EP2830608B8 (en) 2020-01-15
AU2013240219A1 (en) 2014-10-09
IL234825A0 (en) 2014-12-31
EP2830608A4 (en) 2015-08-19
HK1202452A1 (en) 2015-10-02
US9527852B2 (en) 2016-12-27
CA2867175A1 (en) 2013-10-03
MX2014011615A (es) 2015-01-19

Similar Documents

Publication Publication Date Title
JP5699152B2 (ja) リジン特異的デメチラーゼ−１阻害剤およびその使用
CN110198938B (zh) 作为蛋白质聚集调节剂的双-杂芳基衍生物
US12209071B2 (en) Triazine derivatives for treating diseases relating to neurotrophins
KR20160113287A (ko) 단백질 응집 저해제로서의 헤테로아릴 아미드
KR20150031481A (ko) 단백질 응집 저해제로서의 디- 및 트리-헤테로아릴 유도체
AU2015336458B2 (en) KCNQ2-5 channel activator
KR20150002713A (ko) 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체
CN113831301A (zh) 苯并噻唑类衍生物及其用途
JP7100042B2 (ja) タンパク質凝集のモジュレーターとしてのアルコキシビス－ヘテロアリール誘導体
CN102869647B (zh) 作为5-ht6受体配体的砜化合物
KR102639231B1 (ko) 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도
JP6154007B2 (ja) 糖尿病の治療に有用なイミダゾピリジン誘導体
US20190127320A1 (en) Kcnq2-5 channel activator
KR102487130B1 (ko) 신규 메틸설폰아미드 유도체 화합물의 암전이 억제용 조성물
CN109422751A (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
KR102179406B1 (ko) 신규한 인다졸 유도체 및 이의 용도
NZ591833A (en) Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
EA042432B1 (ru) Замещенные фенилсульфонил фенилтриазолтионы и их применение
ITBO20070618A1 (it) Composti organici utili per il trattamento di malattie neurodegenerative, loro utilizzazioni e metodo per la loro preparazione

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141028

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid